Published in J Acquir Immune Defic Syndr on March 01, 2003
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis (2010) 1.77
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med (2008) 1.55
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci (2007) 1.33
Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda. Afr Health Sci (2009) 1.04
Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. ISRN Pediatr (2013) 0.92
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2007) 0.88
Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol (2013) 0.85
Antiretroviral-associated Hepatotoxicity. Curr Infect Dis Rep (2005) 0.84
Development of fatal acute liver failure in HIV-HBV coinfected patients. World J Gastroenterol (2010) 0.83
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play? Eur J Med Res (2009) 0.82
Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals. World J Gastroenterol (2011) 0.82
Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C. Antivir Ther (2014) 0.82
Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy. J Clin Immunol (2011) 0.77
The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection. J Res Med Sci (2015) 0.77
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. J Med Case Rep (2007) 0.76
Dragon's blood and its extracts attenuate radiation-induced oxidative stress in mice. J Radiat Res (2014) 0.76
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis (2004) 3.95
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr (2002) 3.55
Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis (2012) 3.49
GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med (2013) 3.37
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol (2008) 3.14
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infect Dis (2012) 2.78
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis (2013) 2.65
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med (2004) 2.44
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Imported Chikungunya Infection, Italy. Emerg Infect Dis (2007) 2.08
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis (2011) 1.97
Mechanisms of antibacterial action of three monoterpenes. Antimicrob Agents Chemother (2005) 1.92
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst (2006) 1.89
Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma (2006) 1.88
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis (2008) 1.82
Natural history of chronic hepatitis B in co-infected patients. J Hepatol (2005) 1.77
Acute respiratory distress syndrome in Plasmodium vivax malaria in traveler returning from Venezuela. J Travel Med (2006) 1.71
Interaction of four monoterpenes contained in essential oils with model membranes: implications for their antibacterial activity. J Agric Food Chem (2007) 1.71
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther (2004) 1.65
Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials (2002) 1.65
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Management of imported malaria in Europe. Malar J (2012) 1.60
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol (2007) 1.60
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57
T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation (2005) 1.56
Point-of-care screening, prevalence, and risk factors for hepatitis B infection among 3,728 mainly undocumented migrants from non-EU countries in northern Italy. J Travel Med (2014) 1.54
Fibrinogen storage disease caused by Aguadilla mutation presenting with hypobeta-lipoproteinemia and considerable liver disease. J Pediatr Gastroenterol Nutr (2009) 1.50
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49
Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials (2002) 1.48
High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine (2011) 1.43
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. J Antimicrob Chemother (2009) 1.43
Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med (2005) 1.40
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. Fundam Clin Pharmacol (2011) 1.38
Protura of Italy, with a key to species and their distribution. Zookeys (2011) 1.38
CD44-v6 expression in smooth muscle cells in the postnatal remodeling process of ductus arteriosus. Am J Cardiol (2006) 1.38
Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego. HIV Clin Trials (2002) 1.37
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol (2008) 1.36
Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med (2003) 1.36
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin (2004) 1.30
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill (2015) 1.29
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS (2012) 1.29
Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis (2002) 1.28
Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop Med Int Health (2006) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis (2005) 1.23
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res (2007) 1.23
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. Clin Infect Dis (2008) 1.23
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology (2012) 1.20
Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. Emerg Infect Dis (2009) 1.19
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev (2002) 1.18
Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis (2010) 1.18
Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011. Am J Trop Med Hyg (2013) 1.16
Illness in children after international travel: analysis from the GeoSentinel Surveillance Network. Pediatrics (2010) 1.16
Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis (2010) 1.14
Unresectable multifocal omental and peritoneal inflammatory myofibroblastic tumor in a child: revisiting the role of adjuvant therapy. J Pediatr Surg (2011) 1.14
Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine (2010) 1.13
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis (2003) 1.13
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol (2004) 1.12
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis (2012) 1.10
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10